Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Amortization of Deferred Charges (2019 - 2025)

Pulmonx (LUNG) has disclosed Amortization of Deferred Charges for 7 consecutive years, with $14000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Amortization of Deferred Charges rose 27.27% to $14000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $49000.0, a 9.26% decrease, with the full-year FY2024 number at $52000.0, up 8.33% from a year prior.
  • Amortization of Deferred Charges was $14000.0 for Q3 2025 at Pulmonx, up from $13000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $39000.0 in Q1 2021 to a low of $10000.0 in Q4 2022.
  • A 5-year average of $15789.5 and a median of $14000.0 in 2022 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: crashed 94.85% in 2021, then skyrocketed 60.0% in 2024.
  • Pulmonx's Amortization of Deferred Charges stood at $17000.0 in 2021, then crashed by 41.18% to $10000.0 in 2022, then increased by 30.0% to $13000.0 in 2023, then decreased by 15.38% to $11000.0 in 2024, then rose by 27.27% to $14000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Amortization of Deferred Charges are $14000.0 (Q3 2025), $13000.0 (Q2 2025), and $11000.0 (Q1 2025).